Abstract:OBJECTIVE:To investigate the expression of MAGE-B genes in hepatocellular carcinoma (HCC) in order to find new targets for immunotherapy. METHODS:The expression of MAGE-B1, B2, A1 and A3 mRNA was detected using RT-PCR in HCC tissues and the corresponding adjacent non-HCC tissues from 47 HCC patients, 30 samples of cirrhosis and normal liver tissues. Four samples selected randomly from MAGE-B1 or B2 with positive RT-PCR results were sequenced to confirm the results of RT-PCR. The relationship between the expression of MAGE-B and some clinicopathological parameters was analyzed. RESULTS:MAGE-B1 mRNA and MAGE-B2 mRNA were detected in 44.7% (21/47) and 61.7% (29/47) of HCC samples, respectively, while neither MAGE-B1 nor MAGE-B2 could be detected in the corresponding adjacent non-HCC liver tissues. In addition, none of 30 samples of cirrhosis and normal liver tissues was shown to express both MAGE-B genes. The DNA sequence confirmed that the RT-PCR products were truly target cDNA. The frequency of the expression of MAGE-A1 and A3 was 74.5% (35/47) and 44.7% (21/47), respectively. There was significant correlation between the expression of MAGE-B and MAGE-A (P < 0.05). However, the positive expression of MAGE-B was observed in 5 out of 12 HCC tissues without expression of MAGE-A1 and/or A3. When all four MAGE genes were examined, the positive rate of expression of one, two, three and four genes was 83.0% (39/47), 55.3% (26/47), 48.9% (23/47), and 38.3% (18/47) of 47 HCC tissues, respectively. No correlation was found between the expression of MAGE-B and clinical parameters such as age, sex, tumor size, degree of tumor differentiation, serum alpha-fetoprotein level and hepatitis B virus or hepatitis C virus infection (P > 0.05). CONCLUSION:MAGE-B genes are expressed with relatively high frequency and specificity in HCC. Most HCC patients with positive expression of at least one member of MAGE-B or MAGE-A gene family are adequate candidates to receive specific immunotherapy. Frequent co-expression of multiple members of MAGE-B and MAGE-A subfamilies provides the possibility of using polyvalent vaccines to achieve more effective immunotherapeutic results.

[Expression of MAGE-B Genes in Hepatocellular Carcinoma].

Proliferative effect of MAGE-A9 deletion mutant on human breast cancer MCF-7 cells

Expression of the MAGE-1 Gene in Human Hepatocellular Carcinomas

[Expression of MAGE, GAGE, and BAGE Genes in Human Hepatocellular Carcinoma].

MAGE-1 and Related MAGE Gene Expression May Be Associated with Hepatocellular Carcinoma

[Expression and Clinical Significance of MAGE-4 Gene in Human Hepatocellular Carcinoma].

Expression of MAGE-A1 and Its Clinical Signficance in Hepatocellular Carcinoma

Overexpression of MAGE-A9 predicts unfavorable outcome in breast cancer.

Expression of Cancer-Testis Antigens in Hepatocellular Carcinoma

Evaluation of MAGE-1 and MAGE-3 As Tumour-Specific Markers to Detect Blood Dissemination of Hepatocellular Carcinoma Cells.

[Melanoma Antigen-3 Expression in Human Hepatocellular Carcinoma].

Expression of A, G and B melanoma antigen genes in human hepatocellular carcinoma.

A comprehensive analysis of the MAGE family as prognostic and diagnostic markers for hepatocellular carcinoma

Expression of Melanoma Antigen Gene in Cell Lines Originated from Hepatocellular Carcinoma Cells

Specific CD8+ T Cell Responses to HLA-A2 Restricted MAGE-A3 P271–279 Peptide in Hepatocellular Carcinoma Patients Without Vaccination

Mrna of MAGE Genes As Specific Markers in Detection of Tumor Cells in the Peripheral Blood of Patients with Hepatocellular Carcinoma

[Mrna Expressions of MAGE Genes in Human Lung Cancer].

Expression of multiple MAGE genes in colorectal carcinoma

The Expression of Cancer-Testis Antigen MAGE-A1、MAGE-C2 and SSX-1 Mrna in Hepatocellular Carcinoma

Immune Responses to NY--ESO--1 and MAGE--A3 Peptides in Hepatocellular Carcinoma Patients

[Expression of MAGE-1 and MAGE-3 Genes in Gastric Cancer and Gastric Biopsy Tissues and Its Clinical Significance].